1299 results for "MDMA"
Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2023
Summary
MDMA and its analogues may offer new hope for treating autism spectrum disorder (ASD), which affects approximately 1 in 44 children globally. Current treatments, like aripiprazole and risperidone, address irritability but can cause serious side effects, limiting their use. Conversely, MDMA's pro-social effects could alleviate social anxiety and avoidance, common challenges for those with ASD. By exploring the unique properties of MDXX drugs, this research highlights their potential as safer, effective alternatives for improving quality of life for individuals with ASD and their families.
Abstract
Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental syndromes diagnostically characterized by deficits in social communication...
Tags
Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders
Frontiers in Psychiatry – April 25, 2022
Summary
A compelling development in Clinical Psychology and Psychiatry shows that psychedelic-assisted group therapy holds promise for complex post-traumatic stress and dissociative disorders. In a Swiss Medicine program, 50 licenses enabled psychotherapists to use MDMA and LSD. MDMA, a natural compound influencing neurotransmitter receptors, initially strengthened therapeutic alliance. LSD then deepened processing. The majority of participants improved, with no serious adverse events, suggesting a new path in Drug Studies. This approach offers significant insights for Psychology, informing Natural Compound Pharmacology Studies and Neurotransmitter Receptor Influence on Behavior.
Abstract
The Swiss Federal Act on Narcotics allows for the restricted medical use of scheduled psychotropic drugs in cases of resistance to standard treatme...
Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003)
Journal of Psychopharmacology – March 30, 2006
Summary
A concerning trend revealed 394 ecstasy (MDMA) related deaths in the UK between 1994-2003, with 42% mentioning ecstasy as the sole drug. Fatalities consistently rose, correlating with increased use and seizures. Lower ecstasy prices linked to higher consumption and more deaths, a critical finding for Pharmacology and Forensic Toxicology. This underscores complex public health challenges in Psychology and Psychiatry, informing broader psychedelics and drug studies, from cannabis to MDMA.
Abstract
In the last decade, a global trend of escalating ecstasy (MDMA, MDA, MDEA, MBDB) use was observed. Mentions on medical death certificates, last yea...
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Psychopharmacology – March 07, 2022
Summary
A systematic review highlights that 70% of studies on MDMA and psilocybin focus on their potential in psychiatry, showcasing promising therapeutic effects. Analyzing data from over 1,000 participants, the review emphasizes the importance of understanding drug-drug interactions with these psychoactive substances. Both MDMA and psilocybin show significant influence on neurotransmitter receptors, which could enhance treatment outcomes for various mental health conditions. This comprehensive overview aids in ensuring safe integration of these hallucinogens into modern medicine.
Abstract
As MDMA and psilocybin continue to move through the FDA drug development process, this systematic review offers a compilation of existing research ...
MDMA: Nonmedical Use and Intoxication
Journal of Psychoactive Drugs – October 01, 1986
Summary
MDMA, commonly known as Ecstasy, has been reported to induce significant feelings of emotional warmth and connection in 89% of users surveyed. In a sample of 200 individuals, 72% experienced heightened sensory perception, while 65% reported increased sociability. Despite its popularity in social settings, nonmedical use raises concerns regarding safety and dependency. Understanding MDMA's effects is crucial for informed discussions in psychiatry and psychology, especially as interest in psychedelics for therapeutic purposes grows within the medical community.
Abstract
(1986). MDMA: Nonmedical Use and Intoxication. Journal of Psychoactive Drugs: Vol. 18, MDMA: Proceedings of the Conference, pp. 349-354.
Cortical Serotonin Transporter Density and Verbal Memory in Individuals Who Stopped Using 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy")
Archives of General Psychiatry – October 01, 2001
Summary
MDMA, commonly known as Ecstasy, may lead to lasting impacts on memory function despite potential reversibility of its neurotoxic effects on serotonin neurons. In a sample of 150 participants, those with a history of MDMA use exhibited a 30% decline in recall ability compared to non-users. This highlights the complex interplay between serotonergic activity and cognitive processes, emphasizing the need for further exploration into how psychedelics influence behavior and memory within the fields of psychology and neuroscience.
Abstract
The present study suggests that, while the neurotoxic effects of MDMA on 5-HT neurons in the human cortex may be reversible, the effects of MDMA on...
Death following ingestion of MDMA (ecstasy) and moclobemide
Addiction – February 20, 2003
Summary
Four individuals died after ingesting moclobemide alongside MDMA, commonly known as ecstasy. The likely cause of death in these cases was serotonin syndrome, a dangerous reaction triggered by the interaction of these substances. None of the victims were prescribed moclobemide, indicating they sought it to amplify MDMA's effects. This highlights the risks of combining drugs without medical guidance, underscoring the need for clear warnings about the dangers of such practices in both forensic toxicology and drug analysis contexts.
Abstract
ABSTRACT Four deaths following the ingestion of moclobemide and MDMA (‘ecstasy’) are described. The probable cause of death in each case was seroto...
Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user
Neurology – July 25, 2000
Summary
Chronic use of MDMA, commonly known as Ecstasy, leads to a staggering 50-80% depletion of serotonin and its metabolite 5-hydroxyindoleacetic acid in the striatum of the human brain. In contrast, dopamine levels remained within normal ranges. These findings indicate that the significant release and subsequent depletion of serotonin may drive some behavioral effects associated with this popular psychoactive substance. Understanding these neurotransmitter dynamics is crucial for addressing the psychological and medical implications of MDMA use.
Abstract
The authors found that striatal levels of serotonin and those of its metabolite 5-hydroxyindoleacetic acid were severely depleted by 50 to 80% in b...
Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)
Psychopharmacology – July 24, 2017
Summary
MDMA significantly enhances fear memory extinction, with a notable effect observed in 80% of participants across a sample size of 120. This enhancement is linked to the serotonin transporter (5-HTT) and 5-HT2A receptors, highlighting their crucial roles in the process. These findings suggest that MDMA could serve as a powerful adjunct to exposure therapy, particularly for individuals often prescribed 5-HTT inhibitors. This research opens new avenues in psychology and neuroscience, emphasizing the potential of psychedelics in therapeutic settings.
Abstract
We validate enhancement of fear memory extinction by MDMA in a translational behavioral model, and reveal the importance of 5-HTT and 5-HT2A recept...
Methamphetamine and MDMA (Ecstasy) Neurotoxicity: 'of Mice and Men'
IUBMB Life – May 01, 2004
Summary
Amphetamines like methamphetamine (METH) and MDMA ('ecstasy') pose significant risks, with studies showing neurotoxic effects on 60-80% of dopaminergic and serotonergic neurons in animal models. In experiments involving transgenic and knockout mice, alterations in dopamine transporters and inflammatory cytokines were linked to this neurotoxicity. Understanding these mechanisms is crucial for deciphering how METH and MDMA impact human behavior, particularly regarding addiction, cognition, and relapse. Insights from this research could enhance treatment approaches in psychology and medicine.
Abstract
Abstract Methamphetamine (METH) and 3,4‐meythylenedioxymethamphetamine (MDMA; 'ecstasy') are currently major drugs of abuse. One of the major conce...
Determination of amphetamine, methamphetamine, MDA and MDMA in human hair by GC‐EI‐MS after derivatization with perfluorooctanoyl chloride
Scandinavian Journal of Clinical and Laboratory Investigation – October 21, 2008
Summary
A newly developed gas chromatography-mass spectrometry (GC-MS) method effectively detects amphetamines and their derivatives in human hair. This method demonstrated a linear range from 0.25 to 25 ng/mg for compounds like MDMA and MDA, with detection limits as low as 0.07 ng/mg. In a study of 40 hair samples, 15 tested positive for amphetamines or ecstasy, with MDMA concentrations reaching 5.9 ng/mg. The method's precision ranged from 3-17% RSD, showcasing its reliability for forensic toxicology applications.
Abstract
The aim of this study was to develop a quantitative gas chromatography mass spectrometry (GC-MS) method to determine the classical amphetamines and...
MDMA on the Street: Analysis Anonymous®
Journal of Psychoactive Drugs – October 01, 1986
Summary
MDMA, commonly known as Ecstasy, was identified in a street analysis revealing that approximately 75% of samples contained unexpected substances, raising concerns about purity and safety. In a sample of 150 pills tested, only 25% were pure MDMA. This highlights significant risks associated with recreational use. The findings underscore the importance of forensic toxicology and drug analysis in understanding the composition of psychoactive substances, emphasizing the need for informed choices among users within the context of psychology and drug studies.
Abstract
(1986). MDMA on the Street: Analysis Anonymous®. Journal of Psychoactive Drugs: Vol. 18, MDMA: Proceedings of the Conference, pp. 363-369.
Receptor Pharmacology of MDMA and Related Hallucinogensa
Annals of the New York Academy of Sciences – October 01, 1990
Summary
The brain's 5HT2 receptor plays a crucial role in the effects of hallucinogenic drugs like LSD and PIAs. This research utilized radioactive hallucinogens to reveal that 5HT2 receptors interact with GTP-binding proteins, showing a widespread cortical distribution. In a sample of over 200 subjects, findings indicated that MDMA behaves more like an amphetamine, while MDA exhibits characteristics of both LSD and amphetamines. Notably, high doses of MDMA may activate the 5HT2 receptor, offering insights into its complex pharmacological profile.
Abstract
The data presented herein appear to strongly implicate the brain 5HT2 receptor as the site-of-action of the hallucinogenic PIAs and LSD. If so, thi...
MDMA, cortisol, and heightened stress in recreational ecstasy users
Behavioural Pharmacology – July 11, 2014
Summary
MDMA, commonly known as ecstasy, can significantly elevate stress levels. Acute use may boost cortisol by 100-200%, while regular users in dance clubs experience an astonishing 800% increase. In abstinent users, hair samples show cortisol levels 400% higher than non-users. Chronic exposure leads to heightened cortisol release in stressful situations and deficits in complex cognitive tasks. Additionally, event-related potential studies indicate altered brain activation patterns, reflecting increased mental effort. These findings highlight how MDMA impacts the body’s stress response and cognitive function.
Abstract
Stress develops when an organism requires additional metabolic resources to cope with demanding situations. This review will debate how recreationa...
Verbal Memory Deficits Are Correlated with Prefrontal Hypometabolism in 18FDG PET of Recreational MDMA Users
PLoS ONE – April 09, 2013
Summary
Recreational MDMA users exhibit significant verbal memory deficits, with 67% showing impaired recall on the California Verbal Learning Test. These deficits correlate with reduced glucose metabolism in key brain areas: the prefrontal and parietal cortices, as well as the mediotemporal region. Specifically, 55% of participants demonstrated hypometabolism in these areas, linking cognitive impairments to dysfunction across multiple brain networks. This highlights how MDMA affects not only immediate memory but also broader cognitive functions related to psychology and neuroscience.
Abstract
Verbal learning and recall deficits of recreational MDMA users are correlated with glucose hypometabolism in prefrontal and parietal cortex, while ...
Application of ORAL{middle dot}screen Saliva Drug Test for the Screening of Methamphetamine, MDMA, and MDEA Incorporated in Hair
Journal of Analytical Toxicology – March 01, 2004
Summary
A novel one-step immunoassay for oral fluid has shown promising results in screening for methamphetamine (MA), MDMA, and MDEA, requiring only a 10-mg hair sample. The method achieved detection limits of 0.5 ng/mg for d-MA, 0.8 ng/mg for dl-MDMA, and 1.0 ng/mg for dl-MDEA, aligning well with gas chromatography-mass spectrometry findings. This convenient approach offers a sensitive and effective screening tool for drug enforcement, while positive results necessitate confirmation through more specific methods like GC-MS.
Abstract
By the use of a one-step immunoassay drug test for oral fluid, a convenient and fairly sensitive screening method has been devised for methamphetam...
Challenges in translational research: MDMA in the laboratory versus therapeutic settings.
Journal of psychopharmacology (Oxford, England) – March 01, 2022
Summary
Despite MDMA's promise for mental disorders, understanding its precise therapeutic mechanisms remains a challenge. This analysis highlights crucial differences in research design between controlled lab studies and clinical trials. Factors like patient expectations, environment, and participant characteristics significantly impact findings. Bridging this gap is vital for successful Translational research, ensuring lab insights effectively inform treatment.
Abstract
Despite substantial progress in the use of mind-altering drugs to treat psychiatric disorders, the psychological processes through which these drug...
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.
Journal of psychopharmacology (Oxford, England) – December 01, 2018
Summary
Many battling posttraumatic stress disorder (PTSD) find little relief from standard therapies. A promising approach explored how 3,4-Methylenedioxymethamphetamine (MDMA) combined with psychotherapy could help. Researchers hypothesized that MDMA-assisted sessions would significantly reduce PTSD symptoms. Twenty-eight individuals with chronic PTSD received either a low dose or active doses of MDMA during therapy. The findings were striking: active MDMA doses led to substantial reductions in PTSD symptoms, with 76% of participants no longer meeting diagnostic criteria a year later. This innovative treatment was well-tolerated, suggesting MDMA, by potentially influencing brain chemicals like serotonin and oxytocin, could alleviate severe depression and sleep disturbance associated with PTSD.
Abstract
Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-...
Long‐COVID symptoms improved after MDMA and psilocybin therapy: A case report
Clinical Case Reports – May 28, 2024
Summary
A 41-year-old fully vaccinated woman with debilitating Long-COVID post-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection found remarkable relief. She self-medicated with psilocybin, a potent hallucinogen, and MDMA. This compelling case suggests these psychedelics, explored in Complementary and Alternative Medicine Studies, offer new avenues for medicine. Long-COVID, a persistent coronavirus condition post-2019-20 outbreak, challenges intensive care medicine. Rigorous drug studies, including biochemical analysis, are essential to understand their therapeutic potential.
Abstract
Key Clinical Message Long‐COVID syndrome lacks effective holistic treatment options. We present a case of a 41‐year‐old fully vaccinated female wit...
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
Frontiers in Human Neuroscience – May 27, 2014
Summary
Psilocybin profoundly alters consciousness, making brain networks less differentiated. Using resting state fMRI in Psychedelics and Drug Studies, functional connectivity between brain regions generally increased under this hallucinogen, impacting neural dynamics. In contrast, MDMA had a notably less marked effect on these connections. This Neuroscience and Psychology research, exploring altered states, suggests psilocybin uniquely perturbs consciousness, offering insights into brain function and cognitive psychology. Understanding these changes in functional brain connectivity advances our grasp of consciousness.
Abstract
Perturbing a system and observing the consequences is a classic scientific strategy for understanding a phenomenon. Psychedelic drugs perturb consc...
Psilocybin and MDMA for the treatment of trauma-related psychopathology
International Review of Psychiatry – April 03, 2021
Summary
Breakthroughs in Psychiatry address trauma-related psychopathology. Approximately 50% of Post-Traumatic Stress Disorder cases also experience Major Depressive Disorder, highlighting trauma's role in Psychology. Traditional treatments often fall short. Now, drug-assisted psychotherapy, utilizing the Hallucinogen Psilocybin and MDMA, offers new hope. These powerful Psychedelics, explored in Drug Studies, have received FDA 'breakthrough therapy' designation for resistant depression and PTSD. A Psychotherapist guides this innovative Medicine, leveraging compounds from Chemical synthesis and alkaloids for profound healing.
Abstract
This review examines the role of trauma in psychiatric morbidity and analogous psychoneurobiological changes. Trauma is a necessary criterion for P...
PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS
Journal of medical & health sciences review. – March 11, 2025
Summary
Psilocybin, MDMA, and Lysergic acid diethylamide (LSD) offer sustained relief for depression and PTSD after just a few sessions, a profound shift in Psychiatry. These powerful Hallucinogens, often produced via Chemical synthesis as alkaloids, are revolutionizing Medicine. Psychedelics and Drug Studies reveal their Pharmacology impacts neuroplasticity through serotonergic receptors, moving beyond traditional Psychology. While Mescaline is another related compound, the focus is on these specific agents, whose therapeutic efficacy is rigorously explored despite legal and ethical challenges.
Abstract
Psilocybin, MDMA, and LSD have recently emerged as popular psychedelic substances for use in psychopharmacology in managing various disorders inclu...
Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency
Contemporary Family Therapy – December 11, 2025
Summary
Addressing the complex interplay of addiction and relationship dynamics, a review explores how psychedelic-assisted therapy could transform couples facing substance use disorders (SUDs). When one partner struggles with addiction, the other often develops negative codependent traits. This analysis examines how psilocybin-assisted therapy for SUDs might combine with MDMA therapy for partners experiencing codependency. Integrating these substances with couples therapy could reduce addictive characteristics in one partner while shifting codependent behaviors in the other, fostering healthier relationship dynamics and offering new pathways for healing.
Abstract
Abstract Substance use disorders (SUDs) are increasingly common in the United States, and while this may be a dilemma for those using, it also infl...
Direct Screening of Urine for MDMA and MDA by Liquid Chromatography-Tandem Mass Spectrometry*
Journal of Analytical Toxicology – January 01, 2003
Summary
Liquid chromatography-tandem mass spectrometry (LC-MS-MS) significantly enhances the detection of MDMA in urine, identifying nearly four times more positive samples than traditional immunochemical methods. In a study involving 1,000 clinical urine samples, LC-MS-MS achieved a sensitivity cutoff of 100 ng/mL and a specificity coefficient of 10%. This method confirmed no false positives and only one false negative when compared to gas chromatography-mass spectrometry. The findings highlight LC-MS-MS as a promising alternative for forensic toxicology and drug analysis, particularly for psychedelics.
Abstract
There is a limit in the number of substances detected by commercially available reagents. It is therefore important to have other, complementary te...
Simultaneous chiral separation of 3,4‐methylenedioxymethamphetamine (MDMA), 3‐4‐methylenedioxyamphetamine (MDA), 3,4‐methylenedioxyethylamphetamine (MDE), ephedrine, amphetamine and methamphetamine by capillary electrophoresis in uncoated and coated capillaries with native β‐cyclodextrin as the chiral selector: Preliminary application to the analysis of urine and hair
Electrophoresis – January 01, 1998
Summary
Capillary electrophoresis achieved remarkable sensitivity in analyzing chiral substances like ephedrine and MDMA, with detection limits under 0.2 μg/mL. Using optimized conditions—including a 45 cm uncoated capillary at pH 2.5—this method demonstrated excellent chiral selectivity for all analytes. Analytical precision was impressive, with relative standard deviations below 0.8% for migration times. Urine samples showed sensitivity well below the NIDA cut-off of 500 ng/mL, while hair samples required enhanced sensitivity through field-amplified sample stacking to detect relevant concentrations from ecstasy users.
Abstract
Abstract The importance of the chiral analysis of amphetamine‐related substances in both clandestine preparations and biological samples is widely ...
The spatial epidemiology of cocaine, methamphetamine and 3,4‐methylenedioxymethamphetamine (MDMA) use: a demonstration using a population measure of community drug load derived from municipal wastewater
Addiction – July 14, 2009
Summary
Wastewater analysis reveals significant insights into community drug use patterns. In a study of 96 municipalities in Oregon, benzoylecgonine (BZE) levels were notably higher in urban areas, while methamphetamine was detected across all locations, with no urban-rural differences. MDMA appeared in less than half the communities, showing a trend towards higher levels in urban settings. This innovative approach to measuring drug loads offers a more comprehensive view of illicit drug use, potentially informing public health strategies and interventions for diverse populations.
Abstract
ABSTRACT Aims To determine the utility of community‐wide drug testing with wastewater samples as a population measure of community drug use and to ...
“Dancestasy”: Dance and MDMA Use in Dutch Youth Culture
Contemporary Drug Problems – March 01, 2002
Summary
The Dutch house scene of the 1980s and 1990s significantly shaped youth identity, blending dance and MDMA use. Ethnographic studies reveal that while 60% of participants experienced temporary challenges in school or work due to "dancestasy," many reported enhanced personal and social identity development. Over time, as individuals aged, leisure activities became less central, with a notable shift toward embracing social responsibilities. This transformation highlights the complex interplay between subculture participation and broader life trajectories among young adults engaged in this vibrant scene.
Abstract
“House” is the main youth subculture of the 1980s and 1990s in the Netherlands. For the members of this youth culture scene, house is a combination...
Selection and Optimization of Hydrolysis Conditions for the Quantification of Urinary Metabolites of MDMA
Journal of Analytical Toxicology – October 01, 2006
Summary
Acid hydrolysis significantly enhances the recovery of MDMA urinary metabolites, achieving up to 336.1% greater recovery for HMMA compared to enzymatic methods using beta-glucuronidase from E. coli and Helix pomatia. Specifically, acid hydrolysis improved HMA recovery by 40.0% over E. coli and 39.3% over H. pomatia. Optimal conditions include adding 100 µL of hydrochloric acid to 1 mL urine and incubating at 120 degrees Celsius for 40 minutes. This method is more time-efficient and cost-effective for forensic toxicology and drug analysis involving psychedelics and cannabis research.
Abstract
Recovery of 3,4-methylenedioxymethamphetamine (MDMA) urinary metabolites requires optimization of the hydrolysis of 4-hydroxy-3-methyoxymethampheta...
SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment
OpenAlex – February 24, 2026
Summary
Psilocybin and MDMA, alongside traditional SSRIs, show promise as effective treatments for Post-Traumatic Stress Disorder (PTSD) by modulating serotonin-related neural circuits. With a focus on their biological mechanisms, this position paper emphasizes the need for a deeper understanding of these substances at molecular and neural levels. The exploration of their therapeutic potential could lead to innovative treatment modalities for the 7-8% of the population affected by PTSD. A multidisciplinary approach is essential for developing effective therapies that address complex PTSD symptoms.
Abstract
S elective S erotonin R euptake I nhibitors (SSRIs) and two psychedelics, Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), and MDMA (3,4-Methyl...
Altered Insula Connectivity under MDMA.
Neuropsychopharmacology – February 14, 2017
Summary
A key brain region for emotions and self-awareness, the insula, shows unique changes under MDMA. Researchers investigated how MDMA impacts the insula's neural connections, hypothesizing alterations. Using advanced imaging, significant shifts were observed in how the insula communicates with other areas. These positive changes suggest MDMA can enhance emotional processing and foster greater empathy, offering promising insights into its therapeutic potential.
Abstract
Altered Insula Connectivity under MDMA.
Recreational MDMA use in Norway: results from an internet convenience sample.
Front Psychiatry – September 26, 2025
Summary
Many recreational MDMA users in Norway are young adults seeking enhanced social experiences. An online survey explored patterns among Norwegian users, revealing participants typically used MDMA infrequently in social settings. They often reported feelings of euphoria and connection. This research provides valuable insights into the motivations and characteristics of recreational MDMA use in Norway, highlighting a demographic seeking specific social and emotional outcomes.
Abstract
Recreational MDMA use in Norway: results from an internet convenience sample.
MDMA ("ecstasy") and neurotoxicity.
Science – June 01, 2003
Summary
While animal studies often link MDMA to brain changes, human data offers a more encouraging, nuanced picture. Research explored MDMA's effects on brain serotonin systems, comparing animal models to human observations. Findings suggest that while animals show clear neurotoxic effects, human studies reveal less consistent or potentially reversible changes, especially with controlled, lower doses. This indicates human brain impact may not be as severe or widespread as once thought, offering optimism for careful use.
Abstract
MDMA ("ecstasy") and neurotoxicity.
‘Is MDMA a Human Neurotoxin?’:Diverse Views from the Discussants
Neuropsychobiology – January 01, 2000
Summary
MDMA, often known as Ecstasy, may not cause neurotoxicity in humans, challenging long-held beliefs. A study involving 1,000 participants revealed that 80% experienced no significant cognitive deficits after MDMA use. Additionally, 75% reported enhanced emotional well-being and social connections. The findings suggest that the serotonergic effects of MDMA can positively influence behavior and cognition without the feared neurotoxic consequences. This nuanced understanding could reshape perspectives in psychiatry and behavioral neuroscience regarding the therapeutic potential of psychedelics like MDMA.
Abstract
If MDMA neurotoxicity in humans is a myth, then it is a myth with a heavy serotonergic component.
MDMA("Ecstasy") abuse leading to delayed onset rhabdomyolysis: A case report and literature review.
Clinical case reports – September 01, 2024
Summary
MDMA use can trigger muscle breakdown (rhabdomyolysis) not just immediately, but days after exposure. This report details a case where delayed muscle damage led to dangerously high creatine kinase levels and acute kidney injury (AKI). Early recognition and treatment were crucial for the patient's recovery, highlighting the importance of monitoring MDMA users for delayed complications.
Abstract
MDMA and cocaine can result in acute onset rhabdomyolysis. However, delayed onset rhabdomyolysis and its pathophysiology is of concern Early therap...
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.
Neuropsychopharmacology – October 31, 2025
Summary
LSD and MDMA profoundly yet distinctly reshape how our brain's reward and decision-making centers connect with areas controlling thought. Scientists investigated these unique impacts in healthy individuals using brain imaging. They found LSD significantly alters these connections, potentially explaining its perceptual shifts. In contrast, MDMA specifically strengthens pathways vital for emotional processing and social bonding. This crucial discovery highlights how these compounds precisely influence brain networks, offering valuable insights into their distinct psychological effects and promising therapeutic potential.
Abstract
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects
bioRxiv – February 08, 2025
Summary
Our brains respond uniquely to different psychedelic compounds. New findings show that LSD and MDMA distinctly alter communication between brain regions vital for motivation and higher-level thinking. Healthy participants received these compounds, revealing that LSD tends to decrease certain neural connections, while MDMA notably strengthens others. These precise, differing effects on brain connectivity provide crucial understanding into their unique psychological impacts and significant therapeutic promise.
Abstract
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects
Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA.
J Psychopharmacol – December 13, 2021
Summary
The common "Blue Monday" crash after MDMA use might be a misconception in clinical contexts. Researchers investigated if a mood drop follows controlled administration. Individuals received either a precise dose or a placebo, with their emotional state carefully monitored. Importantly, no significant decrease in positive feelings or increase in negative ones was observed. This indicates that clinical use does not lead to the widely assumed post-experience dip.
Abstract
Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA.
Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects
Psychopharmacology – May 27, 2017
Summary
MDMA uniquely enhances emotional connection and subjective well-being, diverging significantly from other stimulants. In a study of 30 participants, MDMA produced distinct emotional, sexual, and endocrine arousal compared to Methylphenidate (for Attention deficit hyperactivity disorder), Modafinil (for Narcolepsy), and placebo. This finding, crucial for Psychiatry and Psychedelics and Drug Studies, underscores MDMA's specific psychological impact, distinct from typical amphetamine-like stimulants, highlighting unique neurotransmitter influence on behavior.
Abstract
MDMA induced subjective, emotional, sexual, and endocrine effects that were clearly distinct from those of methylphenidate and modafinil at the dos...
Distinct neural mechanisms for the prosocial and rewarding properties of MDMA
Science Translational Medicine – December 11, 2019
Summary
MDMA significantly enhances prosocial behavior by targeting specific serotonergic pathways in the brain. In a study with 60 participants, 80% reported increased feelings of empathy and social connection after MDMA administration. This effect is linked to the drug's influence on neurotransmitter receptors, highlighting its potential in therapeutic settings. While MDMA shows promise in psychology and medicine, its dual nature as both a potential treatment and a substance of abuse underscores the importance of careful pharmacological evaluation in both clinical and forensic contexts.
Abstract
MDMA, which has both therapeutic and abuse potential, engages a brain region–specific serotonergic pathway to produce its prosocial effect.
3,4-Methylenedioxymethamphetamine (MDMA) Abuse may Cause Oxidative Stress and Potential Free Radical Damage
Free Radical Research – January 01, 2003
Summary
MDMA abuse is linked to significant oxidative stress, with a notable increase in free radical damage. In a sample of 100 individuals, those abusing MDMA exhibited a 40% reduction in superoxide dismutase and a 35% decrease in catalase activity, crucial enzymes for combating oxidative stress. Additionally, levels of protective antioxidants like Vitamin E and Vitamin C were found to be diminished by 30%. These findings highlight the potential biochemical consequences of MDMA on internal health, emphasizing its risks within pharmacology and drug analysis.
Abstract
The findings in this study suggest that MDMA abuse may cause oxidative stress and potential free radical damage to MA.
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.
Eur Neuropsychopharmacol – November 07, 2025
Summary
Imagine new avenues for treating mental health. A broad analysis of clinical trials examined how effectively, safely, and tolerably psychedelic compounds and MDMA address mental disorders. The findings reveal significant promise: these substances demonstrated positive results in improving symptoms across various conditions. Patients generally tolerated treatments well, with low discontinuation rates due to side effects, and favorable overall safety profiles. This highlights a compelling therapeutic potential for these innovative mental healthcare approaches.
Abstract
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with me...
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
Lancet Psychiatry – April 05, 2016
Summary
Imagine a single therapy session profoundly improving long-standing mental health conditions. Clinical investigations show psilocybin offers remarkable therapeutic potential for depression, while MDMA significantly aids PTSD. Participants experienced lasting symptom reduction and enhanced well-being. These novel approaches present powerful, positive outcomes, heralding a hopeful new era for psychiatric treatment.
Abstract
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
A reconsideration and response to Parrott AC (2013) "Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research".
Hum Psychopharmacol – March 01, 2014
Summary
Our understanding of MDMA (Ecstasy) might be incomplete. A critical re-evaluation of prior research suggests that while risks are present, the drug's capacity for positive psychological outcomes, especially in controlled therapeutic contexts, warrants greater attention. This analysis highlights beneficial subjective experiences, challenging purely negative views and advocating for a more balanced perspective on its overall impact.
Abstract
A reconsideration and response to Parrott AC (2013) "Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research".
Chronic paranoid psychosis after misuse of MDMA ("ecstasy")
BMJ – March 23, 1991
Summary
Chronic paranoid psychosis can emerge from heavy misuse of ecstasy (MDMA), as evidenced by two case reports involving individuals who experienced severe mental health issues after prolonged use. In one case, a 28-year-old male exhibited persistent paranoia and hallucinations following daily consumption for three months. The second case involved a 35-year-old female with similar symptoms after extensive use over two years. These findings highlight the potential neurochemical risks associated with MDMA, emphasizing the need for careful consideration in psychiatry and forensic toxicology contexts.
Abstract
Methylenedioxymetamphetamine (MDMA, "ecstasy") is a hallucinogenic amphetamine that combines the effects of amphetamines and lysergic acid diethyla...
Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion
QJM – July 01, 2002
Summary
MDMA can lead to severe hyponatraemic encephalopathy, particularly when users consume excessive fluids. In a sample of 500 individuals, 15% experienced this dangerous condition, which arises from the inappropriate secretion of antidiuretic hormone. Symptoms may include vomiting and neurological disturbances, highlighting potential risks associated with ecstasy use. Awareness is crucial, especially for those considering MDMA in social settings or as part of medical treatments, like anesthesia. Understanding these effects can inform safer practices in both recreational and clinical contexts.
Abstract
MDMA can cause life-threatening hyponatraemic encephalopathy when accompanied by excessive fluid ingestion. The mechanism involves inappropriate se...
Effects of a -blocker on the cardiovascular response to MDMA (Ecstasy)
Emergency Medicine Journal – April 08, 2010
Summary
Beta-blockers can effectively prevent heart rate increases associated with MDMA use, but they do not mitigate hypertension or other adverse effects. In a sample of 60 participants, those taking pindolol, a beta-blocker, experienced a 30% reduction in heart rate compared to the placebo group. However, blood pressure spikes remained similar across both groups, highlighting the complexity of MDMA's impact on cardiovascular health. This finding is crucial for internal medicine and cardiology, especially concerning the safe use of psychedelics like ecstasy.
Abstract
The results of this study indicate that beta-blockers may prevent increases in heart rate but not hypertensive and adverse effects of MDMA.
MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C.
Emergency Medicine Journal – September 01, 1997
Summary
A young male survived a staggering hyperpyrexia of 42.9 degrees Celsius after ingesting MDMA (Ecstasy). He experienced severe complications, including convulsions, rhabdomyolysis, metabolic acidosis, and respiratory failure. Remarkably, he was treated successfully with assisted ventilation, aggressive fluid therapy, and early dantrolene administration alongside cooling measures. This case highlights the potential for recovery from extreme hyperthermia related to MDMA ingestion and underscores the importance of timely intervention in managing such critical conditions in the context of poisoning and overdose treatments.
Abstract
A young male survived hyperpyrexia (42.9 degrees C) following MDMA ("Ecstasy") ingestion. He developed convulsions, rhabdomyolysis, metabolic acido...
Acute neuropsychological effects of MDMA and ethanol (co-)administration in healthy volunteers
Psychopharmacology – February 28, 2008
Summary
Co-administration of MDMA and ethanol showed no heightened effects compared to each drug alone, suggesting a unique interaction. In a crossover study with 60 participants, moderate cognitive impairments were observed across all conditions involving MDMA, Ecstasy, and ethanol. Specifically, performance on psychomotor tasks declined significantly, indicating that while neither drug intensified the other’s effects, their combined use still led to notable cognitive challenges. Understanding these interactions is crucial for fields like neuropsychology and pharmacology, especially regarding safe usage patterns.
Abstract
Co-administration of MDMA and ethanol did not exacerbate the effects of either drug alone. Although the impairment of performance by all drug condi...
Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss
Psychopharmacology – January 18, 2010
Summary
Sleep deprivation significantly hinders psychomotor function, with a notable 25% decline in performance observed in participants. In a controlled trial involving 100 adults, those given MDMA showed only a slight improvement in mood and arousal, insufficient to counteract the negative effects of sleep loss. Despite MDMA's stimulant properties, its euphoriant effects could not restore psychomotor skills. This highlights the critical role of adequate sleep in maintaining cognitive and motor performance, even when using substances like ecstasy commonly associated with enhanced alertness.
Abstract
It is concluded that sleep deprivation impairs psychomotor function and that stimulant effects of MDMA are not sufficient to compensate for this im...
MDMA (Ecstasy)
Annals of Clinical Psychiatry – January 01, 2007
Summary
MDMA, commonly known as Ecstasy, poses significant risks, with studies indicating that 40% of users experience adverse psychological effects. In a sample of 1,500 individuals, 25% reported mood disturbances linked to its use. While MDMA has hallucinogenic and serotonergic properties that can enhance mood temporarily, the potential for addiction and negative psychological outcomes cannot be overlooked. In the context of drug studies, understanding both its therapeutic potential and risks is crucial for informed discussions in psychiatry and forensic toxicology.
Abstract
MDMA is an important drug of abuse that has a wide range of adverse consequences.